An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens

Authors
Publication date
1 January 2012
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Archivio della Ricerca - Università di Pisa

    redirect
    oaioai:arpi.unipi.it:11568/155218
    Last time updated on 13/04/2017